Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Anti-GPRC5D-CD19 CAR-T in R/R Multiple Myeloma
NCT06298266Phase 1Not yet recruiting
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GPRC5D-CD19 CAR T in multiple myeloma (MM), sponsored by Guangdong Second Provincial General Hospital. Primary endpoint: Objective Response Rate at Month 24. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
GPRC5D-CD19 CAR T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06298266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298266.